NASDAQ:VRDN
Viridian Therapeutics
- Stock
13.74
+1.40%
−5.11
This will be loaded shortly.
Loading
This is also still loading.
This will be loaded shortly.
Loading
This is also still loading.
This will be loaded shortly.
Loading
This is also still loading.
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeti...Show More
Earnings
Earnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus